This document provides an overview and market analysis of the global ophthalmic drugs market from 2015 to 2025. It discusses key segments such as retinal disorders, glaucoma, dry eye, and allergic/inflammatory drugs. The market is led by drugs for retinal disorders including Lucentis, Eylea, and Avastin. The US is the largest market, followed by key regions in Europe and Asia. Leading companies discussed are Novartis, Allergan, Roche, and Pfizer. The market is expected to grow due to an aging population and increasing prevalence of eye diseases.
For an Executive Summary of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website: https://www.visiongain.com/blog/pha0128-ss
Top 25 Ophtalmic Drug Manufacturers 2014-2024Visiongain
ย
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1186/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2014-2024
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1404/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2015-2025
Global Antibacterial Drugs Market 2017-2027Visiongain
ย
For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1821/Global-Antibacterial-Drugs-Market-2017-2027
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
ย
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Masters of the Industry at OIS@AAO 2016.
Moderated By:
Jim Mazzo, Global President Ophthalmic Devices - Carl Zeiss Meditec
Participants:
Flemming Ornskov, MD, CEO - Shire
Mike Ball, CEO - Alcon
Ashley McEvoy, Company Group Chairman - Johnson & Johnson Vision Care
William J. Link, PhD, Managing Director - Versant Ventures
Ludwin Monz, PhD, President & CEO - Carl Zeiss Meditec
William Meury, Chief Commercial Officer - Allergan
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
For an Executive Summary of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website: https://www.visiongain.com/blog/pha0128-ss
Top 25 Ophtalmic Drug Manufacturers 2014-2024Visiongain
ย
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1186/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2014-2024
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1404/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2015-2025
Global Antibacterial Drugs Market 2017-2027Visiongain
ย
For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1821/Global-Antibacterial-Drugs-Market-2017-2027
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
ย
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Masters of the Industry at OIS@AAO 2016.
Moderated By:
Jim Mazzo, Global President Ophthalmic Devices - Carl Zeiss Meditec
Participants:
Flemming Ornskov, MD, CEO - Shire
Mike Ball, CEO - Alcon
Ashley McEvoy, Company Group Chairman - Johnson & Johnson Vision Care
William J. Link, PhD, Managing Director - Versant Ventures
Ludwin Monz, PhD, President & CEO - Carl Zeiss Meditec
William Meury, Chief Commercial Officer - Allergan
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1272/Ophthalmic-Devices-Market-Forecast-2014-2024
RETINA COMPANY SHOWCASE- Alimera SciencesHealthegy
ย
Panel Discussion by Alimera Sciences at OIS@ASRS 2016.
Participant:
Dan Myers, CEO- Alimera Sciences
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027Visiongain
ย
For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2017-2027
RETINA COMPANY SHOWCASE- Aerie PharmaceuticalsHealthegy
ย
Panel Discussion by Aerie Pharmaceuticals at OIS@ASRS 2016.
Participant:
Casey Kopczynski, Chief Scientific Officer- Aerie Pharmaceuticals
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongainglobal.com (+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1407/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2015-2025
Pharma leader series top 25 ophthalmic drug manufacturers 2015 2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website:
https://www.visiongain.com/Report/1407/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2015-2025
Dry Eye Syndrome Market by Product Type, Distribution Channel, End User 2024-...IMARC Group
ย
The global dry eye syndrome market size reached US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032.
More Info:- https://www.imarcgroup.com/dry-eye-syndrome-market
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1272/Ophthalmic-Devices-Market-Forecast-2014-2024
RETINA COMPANY SHOWCASE- Alimera SciencesHealthegy
ย
Panel Discussion by Alimera Sciences at OIS@ASRS 2016.
Participant:
Dan Myers, CEO- Alimera Sciences
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027Visiongain
ย
For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2017-2027
RETINA COMPANY SHOWCASE- Aerie PharmaceuticalsHealthegy
ย
Panel Discussion by Aerie Pharmaceuticals at OIS@ASRS 2016.
Participant:
Casey Kopczynski, Chief Scientific Officer- Aerie Pharmaceuticals
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongainglobal.com (+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1407/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2015-2025
Pharma leader series top 25 ophthalmic drug manufacturers 2015 2025Visiongain
ย
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website:
https://www.visiongain.com/Report/1407/Pharma-Leader-Series-Top-25-Biosimilar-Drug-Manufacturers-2015-2025
Dry Eye Syndrome Market by Product Type, Distribution Channel, End User 2024-...IMARC Group
ย
The global dry eye syndrome market size reached US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032.
More Info:- https://www.imarcgroup.com/dry-eye-syndrome-market
Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...IMARC Group
ย
The global glaucoma therapeutics market size reached US$ 7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2027, exhibiting a growth rate (CAGR) of 6.52% during 2022-2027.
More Info:- https://www.imarcgroup.com/glaucoma-therapeutics-market
Infantile Spasms Therapeutics Market by Product Type, Distribution Channel, E...IMARC Group
ย
The global infantile spasms therapeutics market size reached US$ 3.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2028, exhibiting a growth rate (CAGR) of 4.2% during 2023-2028.
More Info:- https://www.imarcgroup.com/infantile-spasms-therapeutics-market
Global orphan drug market outlook 2018Rajesh Sarma
ย
โGlobal Orphan Drug Market Outlook 2018โ research report by KuicK Research comprehensive insight on following developments related to global orphan drug market:
Global & Regional Orphan Drug Market Overview
Orphan Drug Designation Criteria Across Key Markets
Market Specific Reimbursement Policy & Regulatory Framework
Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country
Competitive Landscape
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1193/Healthcare-Packaging-Market-Forecast-2014-2024
This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ million by the following Therapeutic Categories: Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 95 companies including many key and niche players such as Akorn, Inc., Alcon, Inc., Allergan, Inc., Alimera Sciences, Inc., Bausch & Lomb, Inc., Genvec, Inc., GlaxoSmithKline Plc, Inspire Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Ophthalmics, Opko Health, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., QLT, Inc., Santen Pharmaceutical Co., and Santen Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Global orphan drug market future outlook 2020Rajesh Sarma
ย
"Global Orphan Drug Market Future Outlook 2020" report highlights:
Global Orphan Drug Market Overview
Global Orphan Drug Market Segment Analysis
FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs
Orphan Drug Designation Criteria & Reimbursement Policy by Region
Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase
Global Orphan Drugs Clinical Pipeline: 697 Drugs
Majority Orphan Drugs in Phase-II Trials: 249 Drugs
Marketed Orphan Drugs: 274 Drugs
Keratitis Market 2023: Epidemiology, Industry Trends, Size, Share And Forecas...frankmorgan27
ย
The rising incidences of bacterial, viral, fungal, or parasitic infections โ where the cornea is directly invaded by microorganisms causing damage and inflammation are primarily fueling the growth of the keratitis market.
Advanced Wound Care World Market 2014-2024Visiongain
ย
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1198/Advanced-Wound-Care-World-Market-Forecast-2014-2024
Asia pacific wound care market global trends, market share, industry size, gr...Shubham Bhosale
ย
FutureWise Market Research has illustrated a report on the Asia Pacific Wound Care Market. The report provides an in-depth analysis of growth trends affecting the market. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business.
The global neonatal ventilator market size reached US$ 423.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 699.7 Million by 2032, exhibiting a growth rate (CAGR) of 5.58% during 2024-2032.
More Info:- https://www.imarcgroup.com/neonatal-ventilator-market
Medical Swabs Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...IMARC Group
ย
The global medical swabs market size reached US$ 3.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 3.7 Billion by 2028, exhibiting a growth rate (CAGR) of 4.6% during 2023-2028.
More Info:- https://www.imarcgroup.com/medical-swabs-market
Global orphan drug market future outlook 2020KuicK Research
ย
"Global Orphan Drug Market Future Outlook 2020" report highlights:
Global Orphan Drug Market Overview
Global Orphan Drug Market Segment Analysis
FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs
Orphan Drug Designation Criteria & Reimbursement Policy by Region
Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase
Global Orphan Drugs Clinical Pipeline: 697 Drugs
Majority Orphan Drugs in Phase-II Trials: 249 Drugs
Marketed Orphan Drugs: 274 Drugs
Endoscope Reprocessing Market PPT: Overview, Dynamics, Trends, Segmentation, ...IMARC Group
ย
The global endoscope reprocessing market size reached US$ 2.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2032, exhibiting a growth rate (CAGR) of 6.8% during 2024-2032.
More Info:- https://www.imarcgroup.com/endoscope-reprocessing-market
Medical Nonwoven Disposables Market Analysis, Size, Share, Growth To 2020 by...Grand View Research
ย
Rapidly growing geriatric population base is another high impact rendering driver for the medical nonwoven disposables market as aging is considered as one of the greatest risk factor for the development of incontinence
For More Information Visit - http://www.grandviewresearch.com/industry-analysis/medical-nonwoven-disposables-market
Similar to Ophthalmic Drugs Market Forecast 2015-2025 (20)
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...BBPMedia1
ย
Marvin neemt je in deze presentatie mee in de voordelen van non-endemic advertising op retail media netwerken. Hij brengt ook de uitdagingen in beeld die de markt op dit moment heeft op het gebied van retail media voor niet-leveranciers.
Retail media wordt gezien als het nieuwe advertising-medium en ook mediabureaus richten massaal retail media-afdelingen op. Merken die niet in de betreffende winkel liggen staan ook nog niet in de rij om op de retail media netwerken te adverteren. Marvin belicht de uitdagingen die er zijn om echt aansluiting te vinden op die markt van non-endemic advertising.
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
ย
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. Youโll also learn
โข Four (4) workplace discipline methods you should consider
โข The best and most practical approach to implementing workplace discipline.
โข Three (3) key tips to maintain a disciplined workplace.
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
ย
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
๐ข Email Access
๐ข Bank Added
๐ข Card Verified
๐ข Full SSN Provided
๐ข Phone Number Access
๐ข Driving License Copy
๐ข Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1โช(218) 203-5951โฌ
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
Remote sensing and monitoring are changing the mining industry for the better. These are providing innovative solutions to long-standing challenges. Those related to exploration, extraction, and overall environmental management by mining technology companies Odisha. These technologies make use of satellite imaging, aerial photography and sensors to collect data that might be inaccessible or from hazardous locations. With the use of this technology, mining operations are becoming increasingly efficient. Let us gain more insight into the key aspects associated with remote sensing and monitoring when it comes to mining.
Memorandum Of Association Constitution of Company.pptseri bangash
ย
www.seribangash.com
A Memorandum of Association (MOA) is a legal document that outlines the fundamental principles and objectives upon which a company operates. It serves as the company's charter or constitution and defines the scope of its activities. Here's a detailed note on the MOA:
Contents of Memorandum of Association:
Name Clause: This clause states the name of the company, which should end with words like "Limited" or "Ltd." for a public limited company and "Private Limited" or "Pvt. Ltd." for a private limited company.
https://seribangash.com/article-of-association-is-legal-doc-of-company/
Registered Office Clause: It specifies the location where the company's registered office is situated. This office is where all official communications and notices are sent.
Objective Clause: This clause delineates the main objectives for which the company is formed. It's important to define these objectives clearly, as the company cannot undertake activities beyond those mentioned in this clause.
www.seribangash.com
Liability Clause: It outlines the extent of liability of the company's members. In the case of companies limited by shares, the liability of members is limited to the amount unpaid on their shares. For companies limited by guarantee, members' liability is limited to the amount they undertake to contribute if the company is wound up.
https://seribangash.com/promotors-is-person-conceived-formation-company/
Capital Clause: This clause specifies the authorized capital of the company, i.e., the maximum amount of share capital the company is authorized to issue. It also mentions the division of this capital into shares and their respective nominal value.
Association Clause: It simply states that the subscribers wish to form a company and agree to become members of it, in accordance with the terms of the MOA.
Importance of Memorandum of Association:
Legal Requirement: The MOA is a legal requirement for the formation of a company. It must be filed with the Registrar of Companies during the incorporation process.
Constitutional Document: It serves as the company's constitutional document, defining its scope, powers, and limitations.
Protection of Members: It protects the interests of the company's members by clearly defining the objectives and limiting their liability.
External Communication: It provides clarity to external parties, such as investors, creditors, and regulatory authorities, regarding the company's objectives and powers.
https://seribangash.com/difference-public-and-private-company-law/
Binding Authority: The company and its members are bound by the provisions of the MOA. Any action taken beyond its scope may be considered ultra vires (beyond the powers) of the company and therefore void.
Amendment of MOA:
While the MOA lays down the company's fundamental principles, it is not entirely immutable. It can be amended, but only under specific circumstances and in compliance with legal procedures. Amendments typically require shareholder
Skye Residences | Extended Stay Residences Near Toronto Airportmarketingjdass
ย
Experience unparalleled EXTENDED STAY and comfort at Skye Residences located just minutes from Toronto Airport. Discover sophisticated accommodations tailored for discerning travelers.
Website Link :
https://skyeresidences.com/
https://skyeresidences.com/about-us/
https://skyeresidences.com/gallery/
https://skyeresidences.com/rooms/
https://skyeresidences.com/near-by-attractions/
https://skyeresidences.com/commute/
https://skyeresidences.com/contact/
https://skyeresidences.com/queen-suite-with-sofa-bed/
https://skyeresidences.com/queen-suite-with-sofa-bed-and-balcony/
https://skyeresidences.com/queen-suite-with-sofa-bed-accessible/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-king-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed-accessible/
#Skye Residences Etobicoke, #Skye Residences Near Toronto Airport, #Skye Residences Toronto, #Skye Hotel Toronto, #Skye Hotel Near Toronto Airport, #Hotel Near Toronto Airport, #Near Toronto Airport Accommodation, #Suites Near Toronto Airport, #Etobicoke Suites Near Airport, #Hotel Near Toronto Pearson International Airport, #Toronto Airport Suite Rentals, #Pearson Airport Hotel Suites
"๐ฉ๐ฌ๐ฎ๐ผ๐ต ๐พ๐ฐ๐ป๐ฏ ๐ป๐ฑ ๐ฐ๐บ ๐ฏ๐จ๐ณ๐ญ ๐ซ๐ถ๐ต๐ฌ"
๐๐ ๐๐จ๐ฆ๐ฌ (๐๐ ๐๐จ๐ฆ๐ฆ๐ฎ๐ง๐ข๐๐๐ญ๐ข๐จ๐ง๐ฌ) is a professional event agency that includes experts in the event-organizing market in Vietnam, Korea, and ASEAN countries. We provide unlimited types of events from Music concerts, Fan meetings, and Culture festivals to Corporate events, Internal company events, Golf tournaments, MICE events, and Exhibitions.
๐๐ ๐๐จ๐ฆ๐ฌ provides unlimited package services including such as Event organizing, Event planning, Event production, Manpower, PR marketing, Design 2D/3D, VIP protocols, Interpreter agency, etc.
Sports events - Golf competitions/billiards competitions/company sports events: dynamic and challenging
โญ ๐ ๐๐๐ญ๐ฎ๐ซ๐๐ ๐ฉ๐ซ๐จ๐ฃ๐๐๐ญ๐ฌ:
โข 2024 BAEKHYUN [Lonsdaleite] IN HO CHI MINH
โข SUPER JUNIOR-L.S.S. THE SHOW : Th3ee Guys in HO CHI MINH
โขFreenBecky 1st Fan Meeting in Vietnam
โขCHILDREN ART EXHIBITION 2024: BEYOND BARRIERS
โข WOW K-Music Festival 2023
โข Winner [CROSS] Tour in HCM
โข Super Show 9 in HCM with Super Junior
โข HCMC - Gyeongsangbuk-do Culture and Tourism Festival
โข Korean Vietnam Partnership - Fair with LG
โข Korean President visits Samsung Electronics R&D Center
โข Vietnam Food Expo with Lotte Wellfood
"๐๐ฏ๐๐ซ๐ฒ ๐๐ฏ๐๐ง๐ญ ๐ข๐ฌ ๐ ๐ฌ๐ญ๐จ๐ซ๐ฒ, ๐ ๐ฌ๐ฉ๐๐๐ข๐๐ฅ ๐ฃ๐จ๐ฎ๐ซ๐ง๐๐ฒ. ๐๐ ๐๐ฅ๐ฐ๐๐ฒ๐ฌ ๐๐๐ฅ๐ข๐๐ฏ๐ ๐ญ๐ก๐๐ญ ๐ฌ๐ก๐จ๐ซ๐ญ๐ฅ๐ฒ ๐ฒ๐จ๐ฎ ๐ฐ๐ข๐ฅ๐ฅ ๐๐ ๐ ๐ฉ๐๐ซ๐ญ ๐จ๐ ๐จ๐ฎ๐ซ ๐ฌ๐ญ๐จ๐ซ๐ข๐๐ฌ."
Improving profitability for small businessBen Wann
ย
In this comprehensive presentation, we will explore strategies and practical tips for enhancing profitability in small businesses. Tailored to meet the unique challenges faced by small enterprises, this session covers various aspects that directly impact the bottom line. Attendees will learn how to optimize operational efficiency, manage expenses, and increase revenue through innovative marketing and customer engagement techniques.
Putting the SPARK into Virtual Training.pptxCynthia Clay
ย
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
As a business owner in Delaware, staying on top of your tax obligations is paramount, especially with the annual deadline for Delaware Franchise Tax looming on March 1. One such obligation is the annual Delaware Franchise Tax, which serves as a crucial requirement for maintaining your companyโs legal standing within the state. While the prospect of handling tax matters may seem daunting, rest assured that the process can be straightforward with the right guidance. In this comprehensive guide, weโll walk you through the steps of filing your Delaware Franchise Tax and provide insights to help you navigate the process effectively.
What are the main advantages of using HR recruiter services.pdfHumanResourceDimensi1
ย
HR recruiter services offer top talents to companies according to their specific needs. They handle all recruitment tasks from job posting to onboarding and help companies concentrate on their business growth. With their expertise and years of experience, they streamline the hiring process and save time and resources for the company.
What are the main advantages of using HR recruiter services.pdf
ย
Ophthalmic Drugs Market Forecast 2015-2025
1. ยฉnotice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior
written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way
any of the material contained in this report. Each purchase and single copy is for personal use only.
Ophthalmic Drugs Market Forecast
2015-2025
Prospects for Leading Companies in Dry Eye, Glaucoma,
Retinal Disorders, Allergic, Inflammatory & Infective Drugs
2. www.visiongain.com
Contents
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments โ An Industry Overview
2.2 The Human Eyes โ Structurally Delicate And Functionally Intricate Organs
2.3 The Global Burden Of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause Of Vision Loss
2.5.1 A Classification Of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors For Glaucoma
2.5.3 Diagnosis Of Glaucoma
1. Report Overview
2. An Introduction To Ophthalmic Drugs
3. www.visiongain.com
Contents
2.5.4 Drug Treatment Of Glaucoma
2.5.5 Laser Treatment And Surgery For Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors For AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis Of Diabetic Retinopathy
2.7.2 Treatment Of Diabetic Retinopathy
2.8 Ocular Allergy And Allergic Conjunctivitis
2.8.1 Diagnosis Of Ocular Allergy
2.8.2 Treatment Of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment Of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment Of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition In This Report
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation Of The Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2014
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2015-2025
3.5 Ophthalmic Drugs: Changing Market Shares By Sector 2015-2025
3. The Global Ophthalmic Drugs Market, 2015-2025
4. www.visiongain.com
Contents
4.1 Leading Products In The Retinal Disorder Drugs Market, 2014
4.2 Retinal Disorders: Market Trends And Developments, 2015
4.2.1 The Rise And Rise Of Lucentis
4.2.2 The Debate Around Off-Label Avastin Use And The Role Of Novartis And Roche
4.2.3 How Likely Is Avastinโs Expansion Into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales And ThromboGenicsโ Efforts To Reverse It
4.2.5 Drug/Device Combination Products Entering The Market
4.2.6 Does Regenerative Medicine Have A Successful Future In Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2015-2025
4.3.1 Retinal Disorder Drugs: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Drugs For The Treatment Of Retinal Disorders
4.5 Lucentis (ranibizumab) โ Roche/ Novartis
4.5.1 Lucentis: Sales Forecast 2015-2025
4.5.2 Less Frequent Dosing Approved In US For Lucentis
4.5.3 New Indications For Lucentis
4.5.4 Possible Combination Therapy Involving Lucentis
4.6 Eylea (aflibercept) - Regeneron/ Bayer/ Santen
4.6.1 Recent Approvals For Eylea
4.6.2 Eylea: Sales Forecast 2015-2025
4.6.3 Possible Combination Therapies Involving Eylea
4.7 Avastin (bevacizumab) - Roche
4.7.1 Avastin: Sales Forecast 2015-2025
4.7.2 Compounding Pharmacies And Safety Risks
4.8 Visudyne (verteporfin) - Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2015-2025
4.9 Jetrea (ocriplasmin) - ThromboGenics/ Novartis
4. The Retinal Disorder Drugs Market: Market Analysis And Forecast
2015-2025
5. www.visiongain.com
Contents
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans For Jetrea
4.9.3 Jetrea: Sales Forecast 2015-2025
4.9.4 Possible Acquisition Move On ThromboGenics
4.9.5 R&D Agreements With Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) - Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) - Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2015-2025
5.1 Leading Products In The Allergic, Inflammatory And Infective Drugs Market, 2014
5.1.1 Allergic, Inflammatory And Infective Drugs: Market Trends And Developments, 2015
5.1.2 The Growth Prospects For Allergic, Inflammatory And Infective Drugs
5.1.3 Topical NSAIDs Launched: Prolensa and Ilevro
5.2 Allergic, Inflammatory And Infective Drugs: Market Forecast 2015-2025
5.2.1 Allergic, Inflammatory And Infective Drugs: Changing Market Shares By Leading
Drugs 2015-2025
5.3 Leading Drugs For The Treatment Of Allergic, Inflammatory And Infective Ophthalmic
Conditions
5.4 Patanol And Pataday (olopatadine) - Alcon (Novartis)
5.4.1 Pataday: Sales Forecast 2015-2025
5.4.2 Impending Generic Competition For Patanol And Pataday
5.4.3 Approval Of Pazeo Solution
5.4.4 Patanol: Sales Forecast 2015-2025
5.5 Vigamox (moxifloxacin) โ Alcon (Novartis)
5.5.1 Intensifying Competition And Generics Drug Challenge To Vigamox
5.5.2 Moxeza: A Next-Generation Form of Vigamox
5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis
And Forecast 2015-2025
6. www.visiongain.com
Contents
5.5.3 Vigamox: Sales Forecast 2015-2025
5.6 TobraDex (tobramycin/dexamethasone) โ Alcon (Novartis)
5.6.1 The Development And Commercialisation Of TobraDex ST
5.6.2 TobraDex: Sales Forecast 2015-2025
5.7 Bromday (bromfenac) - Valeant
5.7.1 Prolensa: A New Formulation Of Bromfenac
5.7.2 Competition From Ilevro/Nevanac
5.7.3 Bromday: Sales Forecast 2015-2025
5.8 Cravit (levofloxacin) - Santen
5.8.1 Cravit: Sales Forecast 2015-2025
5.9 Acular (ketorolac) โ Allergan (Actavis)
5.9.1 Acular: Sales Forecast 2015-2025
5.10 AzaSite (azithromycin) - Akorn
5.10.1 AzaSite: Sales Forecast 2015-2025
5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2015-2025
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products In The Glaucoma Drugs Market, 2014
6.2 Glaucoma Drugs: Market Trends And Developments, 2015
6.2.1 Patent Expiration: A Major Restraint For Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation In Treatments For Glaucoma
6.2.4 Simbrinza: First Beta-Blocker-Free Combination
6.3 Glaucoma Drugs: Market Forecast 2015-2025
6.3.1 Glaucoma Drugs: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Drugs For The Treatment Of Glaucoma
6.5 Lumigan And Ganfort (bimatoprost) โ Allergan (Actavis)
6.5.1 Lumigan And Ganfort: Sales Forecast 2015-2025
6. Glaucoma Drugs Market: Market Analysis And Forecast 2015-
7. www.visiongain.com
Contents
6.6 Xalatan And Xalacom (latanoprost) - Pfizer
6.6.1 Xalatan/Xalacom: Sales Forecast 2015-2025
6.7 Travatan/Travatan Z And DuoTrav (travoprost) - Novartis
6.7.1 Travatan/Travatan Z And DuoTrav: Sales Forecast 2015-2025
6.8 Alphagan/Alphagan P And Combigan (brimonidine) - Allergan
6.8.1 Alphagan/Alphagan P And Combigan: Sales Forecast 2015-2025
6.9 Trusopt And Cosopt/Cosopt PF (dorzolamide) โ Merck/ Santen
6.9.1 Divestment Agreement With Santen And Akorn
6.9.2 Trusopt: Sales Forecast 2015-2025
6.9.3 Cosopt And Cosopt PF: Sales Forecast 2015-2025
6.10 Azopt (brinzolamide) - Novartis
6.10.1 Azopt: Sales Forecast 2015-2025
6.11 Tapros (tafluprost) โ Santen
6.11.1 Tapros: Sales Forecast 2015-2025
6.12 Zioptan (tafluprost) - Akorn
6.12.1 Zioptan: Sales Forecast 2015-2025
6.13 Other Glaucoma Drugs: Sales Forecast 2015-2025
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products In The Dry Eye Drugs Market, 2014
7.2 Dry Eye Drugs: Market Trends And Developments, 2015
7.2.1 Restasis: Patent Elongations And Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused On Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2015-2025
7.3.1 Dry Eye Drugs: Changing Market Shares By Leading Drugs 2015-2025
7.4 Leading Drugs For The Treatment Of Dry Eye
7.5 Restasis (ciclosporin) โ Allergan (Actavis)
7. Dry Eye Drugs Market: Market Analysis And Forecast 2015-2025
8. www.visiongain.com
Contents
7.5.1 Restasis Patent Elongation
7.5.2 Restasis: Sales Forecast 2015-2025
7.6 Refresh Brand Products โ Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2015-2025
7.7 Hyalein (hyaluronic acid) - Santen
7.7.1 Hyalein: Sales Forecast 2015-2025
7.8 Diquas (diaquafosol) - Santen
7.8.1 Diquas: Sales Forecast 2015-2025
7.9 Other Dry Eye Drugs: Sales Forecast 2015-2025
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) - Vanda Pharmaceuticals
7.10.1.1 Hetlioz: Sales Forecast 2015-2025
8.1 The Ophthalmic Drugs Market By Region
8.1.1 The Global Distribution Of Ophthalmic Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Ophthalmic Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will The Rise Of A Biosimilars Market Impact On US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.3 France
8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2015-2025
8. Leading National Markets For Ophthalmic Drugs, 2015-2025
9. www.visiongain.com
Contents
8.5.4 UK
8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2015-2025
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2015-2025
8.7 China
8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China
8.7.2 Price Controls And The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2015-2025
8.8 Brazil
8.8.1 How Will Brazilโs Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.9 Russia
8.9.1 How Will Russiaโs Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.10 India
8.10.1 The Impact Of The Drug Prices Control Order On Indian Pharma
8.10.2 Indiaโs Expansion Of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.11 Mexico
8.11.1 Mexican Healthcare Reform: Introducing Seguro Popular
8.11.2 Are Multinationals Waking Up To Mexicoโs Market Potential?
8.11.3 Mexican Ophthalmic Drugs Market: Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2015-2025
10. www.visiongain.com
Contents
9.1 Ophthalmic Drugs โ A Changing Market Landscape
9.1.1 Leading Companies In The Ophthalmic Drugs Market, 2015
9.1.2 Ophthalmic Drugs Market: Leading Companies Forecast 2015-2025
9.1.3 Ophthalmic Drugs: Changing Market Shares By Leading Companies 2015-2025
9.2 Novartis (Alcon)
9.2.1 Novartis: Ophthalmic Drugs Portfolio, 2015
9.2.2 Novartis: Sales Forecast 2015-2025
9.2.3 Novartis: Ophthalmic Drugs Development Pipeline, 2015
9.2.4 Novartis: Recent Developments
9.2.4.1 Novartis Restructures Following Strategic Review
9.2.4.2 Novartis Licenses Ophthotechโs Fovista
9.3 Allergan (Actavis)
9.3.1 Allergan: Ophthalmic Drugs Portfolio
9.3.2 Allergan: Recent Developments
9.3.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for
Diabetic Macular Oedema
9.3.2.2 How Real Is The Threat Of Generic Restasis?
9.3.2.3 Valeantโs Attempted Takeover Squashed By Actavis Bid
9.3.3 Allergan: Sales Forecast 2015-2025
9.3.4 Allergan: Ophthalmic Drugs Development Pipeline, 2015
9.4 Roche
9.4.1 Roche: Ophthalmic Drugs Portfolio, 2015
9.4.1.1 Lucentis: US Sales Forecast 2015-2025
9.4.2 Roche: Sales Forecast 2015-2025
9.4.3 Roche: Ophthalmic Drugs Development Pipeline, 2015
9.5 Santen
9.5.1 Santen: Ophthalmic Drugs Portfolio, 2015
9. Leading Companies In The Ophthalmic Drugs Market, 2015-2025
14. www.visiongain.com
Contents
10.3.2.3 NVC-422 (auriclosene) - NovaBay
10.3.2.4 Sarilumab - Regeneron
10.3.2.5 V404 PDS - ForSight VISION
10.3.3 Drugs In Phase 1 And Pre-clinical Development For Allergic, Inflammatory and
Infective Ophthalmic Conditions
10.3.3.1 Finafloxacin - MerLion Pharmaceuticals/Novartis
10.4 Drugs For Glaucoma: Development Pipeline, 2015
10.4.1 Drugs In Phase 2&3 Development For Glaucoma
10.4.1.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) - Valeant
10.4.1.2 AMA0076 (ROCK inhibitor) - Amakem
10.4.1.3 Rhopressa (AR-13324; ROCK and NET inhibitor) And Roclatan (PG324;
ROCK inhibitor) - Aerie Pharmaceuticals
10.4.2 Drugs In Phase 1 And Pre-clinical Development For Glaucoma
10.5 Drugs For Dry Eye: Development Pipeline, 2015
10.5.1 Drugs In Phase 3 Development For Dry Eye
10.5.1.1 EBI-005 (IL-1R antagonist) - Eleven Biotherapeutics
10.5.1.2 Lifitegrast (integrin antagonist) - Shire
10.5.1.3 MIM-D3 (tyrosine kinase receptor antagonist) - Valeant
10.5.1.4 SI-614 (modified hyaluronate) - Seikagaku
10.5.2 Drugs In Phase 2 Development For Dry Eye
10.5.2.1 ESBA105 (TNF-alpha antibody) - Alcon (Novartis)
10.5.2.2 Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi
10.6 Other Drugs In The Development Pipeline For Ophthalmic Conditions
10.6.1 Brimonidine For Eye Whitening - Valeant
10.6.2 GS-101 (aganirsen) - Gene Signal
10.6.3 Omidria (phenylephrine/ketorolac) โ Omeros
15. www.visiongain.com
Contents
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 A Healthy R&D Pipeline
11.2.1.2 Advances In Drug Delivery Technologies
11.2.1.3 Support For Reimbursement And Payment Approvals
11.2.1.4 Gene Therapy And RNA Interference Technology
11.2.1.5 New Ophthalmic Therapeutic Applications For Drugs
11.2.1.6 Development Of Neuroprotective Anti-Glaucoma Medications
11.2.1.7 Biomarkers As Tools For Better Diagnosis And Treatment
11.2.2 Weaknesses
11.2.2.1 Patient Adherence To Treatment
11.2.2.2 High Treatment Burden On Patients And Healthcare Providers
11.2.2.3 Under-Diagnosis And Under-Treatment
11.2.3 Opportunities
11.2.3.1 Sustained-Release Ocular Implants
11.2.3.2 The Impact Of A Rapidly Ageing Global Population
11.2.3.3 Increasing Prevalence Of Eye Diseases And Diabetes
11.2.3.4 Glaucoma And Retinal Disorders Will Have the Most-Marked Increases In
Prevalence
11.2.3.5 Unmet Clinical Need In Many Disease Areas
11.2.3.6 Economic Growth In Emerging Market Provide Opportunity For Expansion
11.2.4 Threats
11.2.4.1 Intensifying Price Regulation In The Market
11.2.4.2 Generic Competition โ Likely Erosion Of Sales For Market Leading Brands
11.2.4.3 Rising Costs Of R&D
11. Qualitative Analysis Of The Ophthalmic Drugs Market, 2015-
2025
16. www.visiongain.com
Contents
11.2.4.4 Biosimilars โ A Potent Threat To Ophthalmic Drugsโ Success
11.3 Porterโs Five Force Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
11.3.1 Threat of New Entrants
11.3.2 Rivalry Among Competitors
11.3.3 Power of Suppliers
11.3.4 Threat of Substitutes
11.3.5 Power of Buyers
12.1 Interview with Dr Patrik De Haes, CEO and Mr Wouter Piepers, Global Head Of Corporate
Communications & Investor Relations At ThromboGenics nv
12.1.1 The Ophthalmic Drug Segments Presenting Growth Opportunities
12.1.2 Jetrea As A Game-Changer In The Treatment Of Vitreomacular Adhesion
12.1.3 The Need To Embrace Novel Treatments
12.1.4 Future Plans For Jetrea
12.1.5 Expanding Treatment Indications And Strategies For Maximising Product Potential
12.1.6 Will Jetrea Be A Substitute For Surgery In Vitreomacular Adhesion Patients?
12.1.7 Development Efforts For Jetrea In Retinal Vein Occlusion
12.1.8 Future Prospects For The Ophthalmic Drugs Market
12.2 Interview With A Spokesperson From Akorn Pharmaceuticals
12.2.1 New Formulation Strategies For Cosopt, Zioptan And Azasite
12.2.2 Expansion Plans For Akornโs Ophthalmic Portfolio
12.2.3 Tackling Key Unmet Needs Within Ophthalmics
12.2.4 Akornโs Future Plans For Growth
13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
12. Expert Opinions From Our Primary Research
13. Conclusions
17. www.visiongain.com
Contents
13.2 Leading Sectors In Ophthalmic Drugs In 2014
13.3 Leading Regions In The Ophthalmic Drugs Market In 2014
13.4 Leading Companies In The Ophthalmic Drugs Market, 2014
13.5 What Does The Future Hold For Ophthalmic Drugs?
18. Page 151
www.visiongain.com
Ophthalmic Drugs Market Forecast 2015-2025: Prospects
for Leading Companies in Dry Eye, Glaucoma, Retinal
Disorders, Allergic, Inflammatory & Infective Drugs
Table 6.10 Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2014-2025
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Azopt ($m) 177 166 160 138 130 124 120 122 125 129 133 137
AGR (%) -6.4 -3.6 -13.7 -5.5 -4.6 -3.2 1.2 2.7 3.0 3.2 3.2
CAGR (%) 2014-19
CAGR (%) 2014-25
-6.8 2019-25 1.7
-2.3
Figure 6.13 Azopt: Novartis Sales Forecast ($m, AGR%), 2014-2025
6.11 Tapros (tafluprost) โ Santen
Tapros (tafluprost) is a prostaglandin analogue used to treat open-angle glaucoma and ocular
hypertension. Tapros was launched in 2008. The drug is sold by Akorn under the name Zioptan
and in some countries as Saflutan, while Santen sells tafluprost as Tapros (in Japan) or Taflotan
(in other markets such as South Korea). The drug has been approved in over 30 European
-20.0
-15.0
-10.0
-5.0
0.0
5.0
0
20
40
60
80
100
120
140
160
180
200
AGR(%)
Revenue($m)
Year
Market Size ($m) AGR (%)
Source: Visiongain 2015
Source: Visiongain 2015
19. Page 198
www.visiongain.com
Ophthalmic Drugs Market Forecast 2015-2025: Prospects
for Leading Companies in Dry Eye, Glaucoma, Retinal
Disorders, Allergic, Inflammatory & Infective Drugs
The Italian healthcare system has had to face up to various challenges over the last five years.
Servicio Sanitario Nazionale (SSN), the Italian healthcare system (a universal healthcare system
similar to the UKโs National Health Service), is challenged by decreasing budgets, increasing focus
on chronic diseases and diseases related to the elderly. Austerity measures implemented in June
2010 introduced reimbursement limits for generics, price cuts, requirements for doctors to
prescribe the cheapest generic where possible, a reduction in the pharmacy profit margin of the
end price of a drug, and a levy on drug manufacturers set at 1.83% of the price of the drug to be
paid to regional health authorities. Further regulation was passed in March 2012, and visiongain
believes more changes are likely to follow in the next ten years as the Italian government struggles
to contain healthcare spending.
We forecast the Italian ophthalmic drugs market to grow over the forecast period, from $530m in
2014 to reach $583m in 2019. A CAGR of 1.9% is expected between 2014 and 2019 (Table 8.18
and Figure 8.19). Reductions in healthcare spending and increasing governmental intervention
over pharmaceutical pricing will impact on market growth. We expect low single digit growth in this
market in the second half of the forecast period. The market will grow to $670m in 2025, with a
CAGR of 2.3% between 2019 and 2025 (Table 8.18 and Figure 8.19).
Table 8.18 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%),
2014-2025
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Italy ($m) 530 540 552 562 573 583 594 604 617 632 650 670
AGR (%) 2.0 2.2 1.8 1.9 1.7 1.9 1.8 2.1 2.4 2.8 3.1
CAGR (%) 2014-19
CAGR (%) 2014-25
1.9 2019-25 2.3
2.2
Source: Visiongain 2015
20. Page 246
www.visiongain.com
Ophthalmic Drugs Market Forecast 2015-2025: Prospects
for Leading Companies in Dry Eye, Glaucoma, Retinal
Disorders, Allergic, Inflammatory & Infective Drugs
Clinical trials have shown that Eylea is non-inferior to Lucentis. The two large-scale Phase 3 trials,
VIEW 1 and VIEW 2 compared an Eylea regimen of 2 mg every two months (after three loading
doses) against 0.5 mg of Lucentis monthly, measuring vision maintenance and/or improvement
over a one-year period. Similar levels of effectiveness were demonstrated by both products, with
some ocular adverse events occurring in the Eylea arm (including conjunctival haemorrhage,
macular degeneration, eye pain, retinal haemorrhage and vitreous floaters most commonly) but a
safety profile similar to that of Lucentis demonstrated overall.
9.6.2 Regeneron: Recent Developments
9.6.2.1 Expanding Indications For Eylea
In July 2014, August 2014, and November 2014, the US FDA, European Commission, and the
Japanese Ministry of Health, Labour and Welfare (MHLW), respectively, approved Eylea for the
treatment of diabetic macular edema (DME). In September 2014, the Japanese MHLW approved
Eylea for myopic choroidal neovascularisation (mCNV). Additionally, in October 2014, it was
reported that the FDA had approved the drug for the treatment of macular edema following retinal
vein occlusion (RVO). This includes macular edema following branch retinal vein occlusion
(BRVO).
We note that in November 2014, the FDA was reported to have accepted for priority review the
supplemental biologics application (sBLA) for Eylea for the treatment of diabetic retinopathy in
patients with DME. In March 2015, the FDA approved the drug as a new treatment for diabetic
retinopathy in patients with diabetic macular edema.
9.6.2.2 Eylea/Zaltrap And The Davis-Smyth Patent Agreements
Genentech and Regeneron both own VEGF Trap-related patents. In early 2012, the two
companies settled their patent dispute over infringement of Genentechโs Davis-Smyth patents. The
companies entered into an amended agreement in May 2013. Under this new agreement,
Regeneron receives a global non-exclusive licence to the Davis-Smyth and other patents, for
ophthalmic administration of Eylea. Regeneron will make payments to Genentech based on US
sales of Eylea as well as sales of Eylea manufactured in the US and sold outside the US, until May
2016. In addition, Regeneron had paid a milestone payment and royalties under the original
agreement; these are set to continue. Bayer HealthCare will also share in making payments based
on the proportion of sales made by the company.
21. Page 297
www.visiongain.com
Ophthalmic Drugs Market Forecast 2015-2025: Prospects
for Leading Companies in Dry Eye, Glaucoma, Retinal
Disorders, Allergic, Inflammatory & Infective Drugs
February 2012). Alcon acquired the drug through its acquisition of ESBATech in 2009. Non-
ophthalmic indications for the drug are being developed by Delenex Therapeutics.
10.5.2.2 Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi
Kineret is an IL-1 receptor antagonist already approved for the treatment of moderate to severe
active rheumatoid arthritis since 2001. The drug has also been approved in Europe for the
treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) since November 2013. It has also
been approved in the US for neonatal onset multi-system inflammatory disease (NOMID), the most
severe form of CAPS, since January 2013. The drug is marketed by Swedish Orphan Biovitrum
(Sobi) under license from Amgen.
In June 2013, a study was published in JAMA Ophthalmology on the results of a Phase 1/2 trial of
topical Kineret (anakinra) in 75 patients with dry eye disease. The study found that treatment with
topical anakinra 2.5% for 12 weeks was safe and effective in patients with dry eye disease,
suggesting that Kineret could be a novel therapeutic option for dry eye. We note that the drug does
not appear to be in active development for dry eye by either Amgen or Sobi.
10.6 Other Drugs In The Development Pipeline For Ophthalmic
Conditions
Visiongain has identified some drugs in the development pipeline for other ophthalmic conditions.
Some of these products are profiled in Table 10.11.
Table 10.11 Other Pipeline Products for Ophthalmic Conditions, 2015
Name
Generic name /
Description
Company Indication
GS-101 aganirsen Gene Signal
Neovascular-
associated corneal
graft rejection
Omidria (OMS302) phenylephrine/ketorolac Omeros
Mydriasis during
surgery
DE-109 sirolimus Santen Uveitis
brimonidine brimonidine Valeant Eye whitening
IBI-80090
intraocular mephalan
injection
Icon Bioscience Retinoblastoma
Source: Visiongain 2015
22. Page 317
www.visiongain.com
Ophthalmic Drugs Market Forecast 2015-2025: Prospects
for Leading Companies in Dry Eye, Glaucoma, Retinal
Disorders, Allergic, Inflammatory & Infective Drugs
12. Expert Opinions From Our Primary Research
Visiongain conducted interviews with key opinion leaders within the market for ophthalmic drugs.
The transcripts of one such interview is presented in this chapter of our report
12.1 Interview With Dr Patrik De Haes, CEO And Mr Wouter Piepers,
Global Head Of Corporate Communications & Investor Relations At
ThromboGenics nv
End of May 2015, Visiongain interviewed Dr Patrik De Haes, CEO and Mr Wouter Piepers, global
head of corporate communications and investor relations at ThromboGenics NV. ThromboGenics
is an integrated biopharmaceutical company focused on developing and commercialising
innovative ophthalmic medicines for the treatment of vitreo-retinal diseases.
This includes Jetreaยฎ, the companyโs lead product, as well as a number of pre-clinical projects in
ophthalmology. Topics discussed include Jetrea as a potential treatment for multiple indications,
ThromboGenicsโ development efforts for the drug, and the rising interest for other new
developments within the retina treatment space.
We thank Dr De Haes and Mr Piepers for their time.
12.1.1 The Ophthalmic Drug Segments Presenting Growth Opportunities
Visiongain: Views on the current ophthalmic drugs market and ThromboGenicsโ work in the
market
Wouter Piepers: The ophthalmic drug market is clearly a growing market. Factors that play here
are a global aging population, and an increasing prevalence of eye disorders, such as diabetic
retinopathy and macular degeneration.
Some elements might be slowing down that growth. Lack of awareness among people about eye
disorders, lack of access in certain parts of the world, patent expiration of certain blockbuster
drugs, and -for selective treatments-, physicianโs treatment habits (surgery) preventing broader
acceptance of innovative alternative treatments. We believe that what is good for the patient, will
eventually become more of a standard, and technology developments might offer a way out for
both patient awareness and access to diagnosis and treatment.